Free Trial
NASDAQ:CLGN

CollPlant Biotechnologies (CLGN) Stock Price, News & Analysis

CollPlant Biotechnologies logo
$2.33 -0.09 (-3.72%)
Closing price 08/1/2025 03:57 PM Eastern
Extended Trading
$2.31 -0.02 (-1.07%)
As of 08/1/2025 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About CollPlant Biotechnologies Stock (NASDAQ:CLGN)

Key Stats

Today's Range
$2.22
$2.50
50-Day Range
$1.35
$4.54
52-Week Range
$1.31
$5.45
Volume
20,491 shs
Average Volume
64,108 shs
Market Capitalization
$29.64 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.50
Consensus Rating
Buy

Company Overview

CollPlant Biotechnologies Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
43rd Percentile Overall Score

CLGN MarketRank™: 

CollPlant Biotechnologies scored higher than 43% of companies evaluated by MarketBeat, and ranked 633rd out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    CollPlant Biotechnologies has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    CollPlant Biotechnologies has only been the subject of 1 research reports in the past 90 days.

  • Read more about CollPlant Biotechnologies' stock forecast and price target.
  • Earnings Growth

    Earnings for CollPlant Biotechnologies are expected to grow in the coming year, from ($1.44) to ($0.56) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of CollPlant Biotechnologies is -1.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of CollPlant Biotechnologies is -1.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    CollPlant Biotechnologies has a P/B Ratio of 1.97. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about CollPlant Biotechnologies' valuation and earnings.
  • Percentage of Shares Shorted

    1.28% of the float of CollPlant Biotechnologies has been sold short.
  • Short Interest Ratio / Days to Cover

    CollPlant Biotechnologies has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in CollPlant Biotechnologies has recently increased by 45.61%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    CollPlant Biotechnologies does not currently pay a dividend.

  • Dividend Growth

    CollPlant Biotechnologies does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.28% of the float of CollPlant Biotechnologies has been sold short.
  • Short Interest Ratio / Days to Cover

    CollPlant Biotechnologies has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in CollPlant Biotechnologies has recently increased by 45.61%, indicating that investor sentiment is decreasing significantly.
    • Insider Buying vs. Insider Selling

      In the past three months, CollPlant Biotechnologies insiders have not sold or bought any company stock.

    • Percentage Held by Insiders

      Only 9.60% of the stock of CollPlant Biotechnologies is held by insiders.

    • Percentage Held by Institutions

      Only 21.69% of the stock of CollPlant Biotechnologies is held by institutions.

    • Read more about CollPlant Biotechnologies' insider trading history.
    Receive CLGN Stock News and Ratings via Email

    Sign-up to receive the latest news and ratings for CollPlant Biotechnologies and its competitors with MarketBeat's FREE daily newsletter.

    CLGN Stock News Headlines

    CollPlant Biotechnologies Ltd. (CLGN) - Yahoo Finance
    Man Who Called Nvidia at $1.10 Says Buy This Now...
    In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new company could become the next to soar like Nvidia.
    See More Headlines

    CLGN Stock Analysis - Frequently Asked Questions

    CollPlant Biotechnologies' stock was trading at $3.60 at the start of the year. Since then, CLGN stock has decreased by 35.3% and is now trading at $2.33.

    CollPlant Biotechnologies Ltd. Sponsored ADR (NASDAQ:CLGN) announced its earnings results on Wednesday, June, 4th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.37) by $0.24. The firm earned $2.06 million during the quarter, compared to analysts' expectations of $9.76 million. CollPlant Biotechnologies had a negative trailing twelve-month return on equity of 87.33% and a negative net margin of 560.92%.

    CollPlant Biotechnologies (CLGN) raised $22 million in an initial public offering on Friday, December 9th 2016. The company issued 3,500,000 shares at a price of $6.23 per share. Ladenburg Thalmann served as the underwriter for the IPO and Roth Capital Partners was co-manager.

    CollPlant Biotechnologies' top institutional shareholders include Villere ST Denis J & Co. LLC (4.30%).

    Shares of CLGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

    Based on aggregate information from My MarketBeat watchlists, some other companies that CollPlant Biotechnologies investors own include Enovix (ENVX), Rambus (RMBS), COMPASS Pathways (CMPS), Ginkgo Bioworks (DNA), Globant (GLOB), Luminar Technologies (LAZR) and Saia (SAIA).

    Company Calendar

    Last Earnings
    6/04/2025
    Today
    8/02/2025
    Next Earnings (Estimated)
    8/19/2025
    Fiscal Year End
    12/31/2025

    Industry, Sector and Symbol

    Stock Exchange
    NASDAQ
    Sector
    Medical
    Industry
    MED - BIOMED/GENE
    Sub-Industry
    Medical Equipment
    Current Symbol
    NASDAQ:CLGN
    CIK
    1631487
    Employees
    70
    Year Founded
    N/A

    Price Target and Rating

    High Price Target
    $12.00
    Low Price Target
    $11.00
    Potential Upside/Downside
    +393.6%
    Consensus Rating
    Buy
    Rating Score (0-4)
    3.33
    Research Coverage
    3 Analysts

    Profitability

    EPS (Trailing Twelve Months)
    ($1.22)
    Trailing P/E Ratio
    N/A
    Forward P/E Ratio
    N/A
    P/E Growth
    N/A
    Net Income
    -$16.61 million
    Net Margins
    -560.92%
    Pretax Margin
    -560.92%
    Return on Equity
    -87.33%
    Return on Assets
    -65.31%

    Debt

    Debt-to-Equity Ratio
    N/A
    Current Ratio
    4.48
    Quick Ratio
    4.23

    Sales & Book Value

    Annual Sales
    $510 thousand
    Price / Sales
    58.11
    Cash Flow
    N/A
    Price / Cash Flow
    N/A
    Book Value
    $1.18 per share
    Price / Book
    1.97

    Miscellaneous

    Outstanding Shares
    12,720,000
    Free Float
    11,495,000
    Market Cap
    $29.64 million
    Optionable
    Optionable
    Beta
    1.45

    Social Links

    Beginner's Guide To Retirement Stocks Cover

    Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

    Get This Free Report

    This page (NASDAQ:CLGN) was last updated on 8/3/2025 by MarketBeat.com Staff
    From Our Partners